{"article":{"annotation":{"article_id":"ose-combi-ted-phase2-reports-one-year-survival-results-2026","available_at":"2026-10-19T09:47:57.550547Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"79751c016e7544a6a49508a3bbdb2df47ef7cd8d346515859a56073babb26961","input_sha256":"1d8f54161408e852cc01876db373015cf251b825050289570a2c3f9a956156ae","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"FR","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"]}],"geometry":null,"id":"iso3166-1:FR","kind":"country-or-area","labels":{"ar":"فرنسا","en":"France","es":"Francia","fr":"France"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:20000447","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: cancer","source_urls":["https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"]}],"method":"controlled-rules-v1","rule_id":"cancer","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=de","category":"health","content":{"key_points":[],"paragraphs":["Laut Mitteilung vom 19. Oktober untersuchte die von FoRT gesponserte, internationale, offene und randomisierte Combi-TED-Studie eine Zweitlinienbehandlung bei metastasiertem nicht-kleinzelligem Lungenkrebs. Eingeschlossen waren 106 HLA-A2-positive Patienten an 19 klinischen Zentren in Frankreich, Italien und Spanien. Tedopi wurde entweder mit Docetaxel oder Nivolumab kombiniert und mit Docetaxel allein verglichen.","Primärer Endpunkt war die Gesamtüberlebensrate nach einem Jahr. OSE meldete 47 Prozent für Tedopi plus Docetaxel, 46 Prozent für Tedopi plus Nivolumab und 29 Prozent für Docetaxel allein. Die vorläufige Mitteilung nennt die Gesamtzahl der Teilnehmer, jedoch keine Gruppengrößen oder Konfidenzintervalle für diese Raten. Die ausführlichen Ergebnisse sollen am 25. Oktober beim ESMO-Kongress in Madrid vorgestellt werden."],"sections":[]},"corrections":[],"country":"FR","data":{"blocks":[{"columns":[{"key":"arm","label":{"ar":"ذراع العلاج","de":"Behandlungsarm","en":"Treatment arm","es":"Grupo de tratamiento","fr":"Bras de traitement","pt":"Braço de tratamento","tr":"Tedavi kolu"},"language":"en","type":"text"},{"key":"rate","label":{"ar":"البقاء الإجمالي بعد عام","de":"Gesamtüberleben nach einem Jahr","en":"One-year overall survival","es":"Supervivencia global al año","fr":"Survie globale à un an","pt":"Sobrevivência global ao fim de um ano","tr":"Bir yıllık genel sağkalım"},"type":"number","unit":"percent"}],"description":{"ar":"النتائج التي أوردتها OSE عن دراسة Combi-TED من المرحلة الثانية في بيانها الصادر في 19 أكتوبر 2026.","de":"Im OSE-Kommuniqué vom 19. Oktober 2026 berichtete Ergebnisse der Combi-TED-Phase-2-Studie.","en":"Results reported for the Combi-TED Phase 2 study in OSE’s press release dated 19 October 2026.","es":"Resultados comunicados del ensayo de fase 2 Combi-TED en el comunicado de OSE del 19 de octubre de 2026.","fr":"Résultats rapportés pour l’essai de phase 2 Combi-TED dans le communiqué d’OSE du 19 octobre 2026.","pt":"Resultados comunicados para o ensaio de fase 2 Combi-TED no comunicado da OSE de 19 de outubro de 2026.","tr":"OSE’nin 19 Ekim 2026 tarihli basın açıklamasında Combi-TED Faz 2 çalışması için bildirdiği sonuçlar."},"id":"combi-ted-one-year-survival","methodology":{"ar":"نسب البقاء الإجمالي بعد عام التي أعلنتها الشركة للتجربة العشوائية المفتوحة من المرحلة الثانية. لم تُحسب المعدلات أو تُعدّل. يذكر البيان 106 مشاركين إجمالاً دون أعداد كل مجموعة أو فواصل الثقة لهذه المعدلات.","de":"Vom Unternehmen berichtete Ein-Jahres-Gesamtüberlebensraten der offenen randomisierten Phase-2-Studie. Es wurden keine Raten berechnet oder angepasst. Die Mitteilung nennt insgesamt 106 Patienten, ohne Gruppengrößen oder Konfidenzintervalle für diese Raten.","en":"Company-reported one-year overall-survival percentages for the open-label randomized Phase 2 trial. No rates were calculated or adjusted. The release specifies 106 patients overall, without individual arm sizes or confidence intervals for these rates.","es":"Porcentajes de supervivencia global al año comunicados por la empresa para el ensayo abierto y aleatorizado de fase 2. No se calcularon ni ajustaron tasas. El comunicado indica un total de 106 pacientes, sin tamaños por grupo ni intervalos de confianza de estas tasas.","fr":"Pourcentages de survie globale à un an rapportés par la société pour l’essai ouvert randomisé de phase 2. Aucun taux n’a été calculé ou ajusté. Le communiqué précise un total de 106 patients, sans effectifs par groupe ni intervalles de confiance de ces taux.","pt":"Percentagens de sobrevivência global a um ano comunicadas pela empresa para o ensaio aberto e aleatorizado de fase 2. Não foram calculadas nem ajustadas taxas. O comunicado indica 106 participantes no total, sem efetivos por grupo ou intervalos de confiança destas taxas.","tr":"Açık etiketli, randomize Faz 2 çalışması için şirketin bildirdiği bir yıllık genel sağkalım yüzdeleridir. Oranlar hesaplanmadı veya düzeltilmedi. Açıklama toplam 106 hastayı belirtir, ayrı kol büyüklüklerini ve bu oranların güven aralıklarını vermez."},"rowTranslations":[{"arm":{"ar":"تيدوبي + دوسيتاكسيل","de":"Tedopi + Docetaxel","en":"Tedopi + docetaxel","es":"Tedopi + docetaxel","fr":"Tedopi + docétaxel","pt":"Tedopi + docetaxel","tr":"Tedopi + docetaksel"}},{"arm":{"ar":"تيدوبي + نيفولوماب","de":"Tedopi + Nivolumab","en":"Tedopi + nivolumab","es":"Tedopi + nivolumab","fr":"Tedopi + nivolumab","pt":"Tedopi + nivolumab","tr":"Tedopi + nivolumab"}},{"arm":{"ar":"دوسيتاكسيل وحده","de":"Docetaxel allein","en":"Docetaxel alone","es":"Docetaxel solo","fr":"Docétaxel seul","pt":"Docetaxel isolado","tr":"Yalnız docetaksel"}}],"rows":[{"arm":"Tedopi + docetaxel","rate":47},{"arm":"Tedopi + nivolumab","rate":46},{"arm":"Docetaxel alone","rate":29}],"sourceUrls":["https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"],"title":{"ar":"البقاء الإجمالي بعد عام في تجربة Combi-TED","de":"Gesamtüberleben nach einem Jahr in Combi-TED","en":"One-year overall survival in Combi-TED","es":"Supervivencia global al año en Combi-TED","fr":"Survie globale à un an dans Combi-TED","pt":"Sobrevivência global ao fim de um ano no Combi-TED","tr":"Combi-TED çalışmasında bir yıllık genel sağkalım"},"type":"table","updatedAt":"2026-10-19T08:16:12Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026/data/combi-ted-one-year-survival?lang=de&format=csv","json":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026/data/combi-ted-one-year-survival?lang=de&format=json"},"id":"combi-ted-one-year-survival"}],"data_types":["table"],"editorial_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-b2a13bbd-82b6-5259-9a42-3a17384910b1","event_period":"2026-10-19","event_period_basis":"event-or-reference-period","id":"ose-combi-ted-phase2-reports-one-year-survival-results-2026","image":null,"importance":0.6,"language":"de","modified_at":"2026-10-19T09:46:57+00:00","publication_basis":"publication-record","published_at":"2026-10-19T09:46:57+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Konzeptionelle Darstellung von öffentlicher Gesundheit, Forschung und vernetzten Daten.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"de","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"ose-combi-ted-phase2-reports-one-year-survival-results-2026","sources":[{"checkedAt":"2026-10-19","name":"OSE Immunotherapeutics","publishedAt":"2026-10-19","url":"https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"}],"summary":"Das französische Biotechnologieunternehmen OSE Immunotherapeutics hat am 19. Oktober Ergebnisse der Phase-2-Studie Combi-TED veröffentlicht. Nach Angaben des Unternehmens lagen die Ein-Jahres-Gesamtüberlebensraten in beiden Tedopi-Kombinationsgruppen über der Rate im Arm mit Docetaxel allein.","text":"Das französische Biotechnologieunternehmen OSE Immunotherapeutics hat am 19. Oktober Ergebnisse der Phase-2-Studie Combi-TED veröffentlicht. Nach Angaben des Unternehmens lagen die Ein-Jahres-Gesamtüberlebensraten in beiden Tedopi-Kombinationsgruppen über der Rate im Arm mit Docetaxel allein.\n\nLaut Mitteilung vom 19. Oktober untersuchte die von FoRT gesponserte, internationale, offene und randomisierte Combi-TED-Studie eine Zweitlinienbehandlung bei metastasiertem nicht-kleinzelligem Lungenkrebs. Eingeschlossen waren 106 HLA-A2-positive Patienten an 19 klinischen Zentren in Frankreich, Italien und Spanien. Tedopi wurde entweder mit Docetaxel oder Nivolumab kombiniert und mit Docetaxel allein verglichen.\n\nPrimärer Endpunkt war die Gesamtüberlebensrate nach einem Jahr. OSE meldete 47 Prozent für Tedopi plus Docetaxel, 46 Prozent für Tedopi plus Nivolumab und 29 Prozent für Docetaxel allein. Die vorläufige Mitteilung nennt die Gesamtzahl der Teilnehmer, jedoch keine Gruppengrößen oder Konfidenzintervalle für diese Raten. Die ausführlichen Ergebnisse sollen am 25. Oktober beim ESMO-Kongress in Madrid vorgestellt werden.","title":"OSE Immunotherapeutics veröffentlicht Ein-Jahres-Überlebensdaten der Combi-TED-Studie","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"}],"url":"https://newsverum.com/de/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},"version":"1"}